BioCentury | Apr 10, 2020
Product Development

April 9 Quick Takes: BMS tops off CAR T patent win; plus approval for Braftovi plus Erbitux, Merck, BMS, Liquidia, Circassia-AZ, Bridge

Award swells to $1.2B, plus royalties, in Kite CAR T suit  Bristol Myers Squibb Co. (NYSE:BMY) and Memorial Sloan Kettering Cancer Center will receive at least $1.2 billion from Gilead Sciences Inc. (NASDAQ:GILD) after a...
BioCentury | Dec 19, 2019

Boehringer deal, clinical milestones support Bridge IPO

A big pharma deal and near-term clinical milestones provided enough grist for investors to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs. The strategy of Bridge Biotherapeutics Inc. (KOSDAQ:288330) to translate...
BC Extra | Jul 18, 2019
Company News

Boehringer deal enables Bridge to expand pipeline, take in-house programs further

In the latest sign of success for Bridge's strategy to translate first-in-class compounds discovered in Asia, the Korean biotech granted Boehringer exclusive global rights to its lung fibrosis candidate BBT-877. The partnership is the second...
BC Extra | Apr 1, 2019
Financial News

Bridge raises $27.2M series C led by UTC, Shinhan

Bridge has parlayed a partnership with Daewoong on the South Korean biotech’s lead ulcerative colitis asset into a W31 billion ($27.2 million) series C round, which was led by returning investor UTC Investment Co. and...
BC Week In Review | Dec 21, 2018
Company News

Bridge, Daewoong partner on BBT-401 for ulcerative colitis

Bridge Biotherapeutics Inc. (Seongnam, South Korea) and Daewoong Pharmaceutical Co. Ltd. (KSE:069620) partnered to co-develop BBT-401 to treat ulcerative colitis. Bridge will receive an undisclosed upfront payment and be eligible for up to $40 million...
BC Week In Review | Nov 16, 2018
Clinical News

Bridge's ulcerative colitis candidate headed for Phase II

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said single and multiple ascending doses of oral ulcerative colitis candidate BBT-401 were well tolerated with minimal systemic exposure observed in a Phase I trial in 80 healthy volunteers....
BioCentury | Nov 21, 2016

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
BioCentury | Oct 10, 2016
Emerging Company Profile

Pellino play

Bridge Biotherapeutics Inc. has licensed the first of what it hopes will be many assets it can use its translational expertise to bring through Phase II proof of concept. The South Korean company is seeking...
Items per page:
1 - 8 of 8